Dexycu

Phase 3Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Sep 1, 2022 → Sep 1, 2023

NCT ID

NCT05550350

About Dexycu

Dexycu is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Cataract. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05550350. Target conditions include Cataract.

What happened to similar drugs?

10 of 19 similar drugs in Cataract were approved

Approved (10) Terminated (2) Active (8)

✅Prednisolone acetateNovartisApproved

✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved

✅Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved

✅Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved

✅Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved

✅Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved

✅Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05550350	Phase 3	Withdrawn	Sep 1, 2022	Sep 1, 2023	Cataract
NCT05550363	Phase 3	Withdrawn	Sep 1, 2022	Sep 1, 2023	Cataract

Competing Products

20 competing products in Cataract

See all competitors

Product	Company	Stage	Hype Score
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-303 + Bromday™	Sun Pharmaceutical	Phase 2	35
ISV-305	Sun Pharmaceutical	Phase 3	40
DE-108 + Levofloxacin 0.5%	Santen Pharmaceutical	Phase 3	40
Prednisolone acetate	Novartis	Approved	43
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%	Ocular Therapeutix	Approved	37
Dextenza 0.4Mg Ophthalmic Insert	Ocular Therapeutix	Approved	37
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%	Ocular Therapeutix	Phase 3	34
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]	Ocular Therapeutix	Phase 2/3	24
Dexamethasone 0.4 MG [Dextenza]	Ocular Therapeutix	Approved	37
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetate	Ocular Therapeutix	Approved	37
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic Emulsion	Ocular Therapeutix	Approved	29
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)	EyePoint Pharmaceuticals	Approved	37
Dexycu	EyePoint Pharmaceuticals	Phase 3	26
DEXYCU (dexamethasone intraocular suspension) 9%.	EyePoint Pharmaceuticals	Pre-clinical	20
Dexamethasone + Prednisolone Acetate Ophthalmic	EyePoint Pharmaceuticals	Approved	44
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%	SpyGlass Pharma	Phase 1/2	30
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%	SpyGlass Pharma	Phase 3	41
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%	SpyGlass Pharma	Phase 3	41
OMS302 + OMS302-PE + Vehicle	Omeros Corporation	Phase 1/2	26